We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > momelotinib

News List

Sierra Oncology licenses myelofibrosis candidate from AstraZeneca pharmatimes
August 09, 2021
Under a new agreement, AstraZeneca will licence AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode, to Sierra Oncology.
Sierra’s Momelotinib Granted FDA Fast Track Designation contractpharma
June 20, 2019
Underscores potential for momelotinib to address unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK inhibitor.
Gilead pays $50M to team up with synthetic lethality startup Tango fiercebiotech
November 02, 2018
Gilead is paying $50 million upfront to enter into an immuno-oncology collaboration with Tango Therapeutics. The agreement gives Gilead the option to pick up the worldwide rights to five targets...